Early HHV-6 IgG and IgA responses during acute SARS-CoV-2 infection in relation to long COVID: a multicohort observational study
BACKGROUND: Long COVID is a heterogeneous condition associated with both early immune responses to SARS-CoV-2 and antibody responses to herpesviruses. However, herpesvirus-directed antibody responses during acute SARS-CoV-2 infection and their relationship to subsequent long COVID remain poorly understood. METHODS: We developed a multiplex bead-based serologic assay using recurrent, public peptide epitopes spanning all eight human herpesviruses. Antibody responses were profiled in longitudinal samples from acute SARS-CoV-2 infection and in early post-infection samples from participants in the NIH RECOVER observational cohort. IgG, IgA, and IgM responses were analysed using peptide-, virus-, and factor-level approaches. FINDINGS: During acute SARS-CoV-2 infection, a subset of individuals exhibited increased herpesvirus-directed IgA responses, particularly against beta-herpesviruses, without corresponding increases in IgG or IgM. In RECOVER participants, subsequent long COVID was associated with herpesvirus- and isotype-specific enrichment of high responders, most prominently HHV-6 IgA and HHV-1/HHV-2 IgG. Unsupervised factorisation identified distinct HHV-6 IgG- and IgA-dominant antibody programs with differing clinical and demographic associations. HHV-6 IgG responses were associated with lower symptom burden and relative enrichment among participants without long COVID, whereas HHV-6 IgA responses were associated with greater symptom burden. HHV-6 IgG responses also declined with increasing age, with the association more readily detected among females. INTERPRETATION: Early herpesvirus-directed antibody responses following SARS-CoV-2 infection exhibit distinct virus- and isotype-specific patterns associated with long COVID. These findings suggest that heterogeneity in long COVID may be linked to differential herpesvirus-directed humoural immune responses that emerge early after infection. FUNDING: This study was funded by Stanford Post-Acute Recovery Cohort; NIH and RECOVER grants; the Henry Gustav Floren Family Trust; the Stanford Department of Medicine Team Science Program; Stanford Institutes of Medicine Summer Research Program (SIMR); the Doris Duke Charitable Foundation; the SPARK Program; Nucleate Dojo; the Jessica Lynn Saal Memorial Award; the William and Marissa Rastetter Research Scholar Fund through the Robinson Life Sciences, Business, and Entrepreneurship Program; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health Award.
Authors
- Xihui Yin (ORCID: https://orcid.org/0000-0002-1861-1147)
- Tyler R. Prestwood (ORCID: https://orcid.org/0000-0002-0971-5286)
- Gabrielle S. Ndakwah
- Ananya Choudhury (ORCID: https://orcid.org/0000-0002-3561-6580)
- Marlayna Harris
- Alysa Rallistan
- Paul J Utz
- Michael J. Burry
- Woo Joo Kwon (ORCID: https://orcid.org/0009-0005-5767-6559)
- Jennifer Frankovich
- Jenna Bollyky
- Emily Q. Cheng
- Sonia Presti
- Elizabeth W. Karlson
- Muge Kalaycioglu
Institutions
- Brigham and Women's Hospital (US)
- Palo Alto University (US)
- VA Palo Alto Health Care System (US)
- Stanford Health Care (US)
- Stanford Medicine (US)
- Institute of Infection and Immunity (CA)
- Stanford University (US)
Publication Details
- Journal
- EBioMedicine
- Published
- 2026-08-27
- DOI
- https://doi.org/10.1016/j.ebiom.2026.106455
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Heart, Lung, and Blood Institute
- National Institute of Mental Health
- National Institute of Diabetes and Digestive and Kidney Diseases